<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605094</url>
  </required_header>
  <id_info>
    <org_study_id>D3256C00001</org_study_id>
    <nct_id>NCT04605094</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis</brief_title>
  <official_title>A Phase 2 Multinational, Randomized, Double-blind, Parallel-group, 16-week Placebo-controlled Study With a 36-Week Extension to Investigate the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis Despite Treatment With Topical Medications (The HILLIER Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the efficacy and safety of benralizumab versus placebo&#xD;
      and to compare benralizumab dosing regimens during extension period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to investigate the use of benralizumab as treatment for patients&#xD;
      with moderate to severe atopic dermatitis (AD) who remain symptomatic despite treatment with&#xD;
      topical medications. It is proposed that benralizumab will deplete eosinophils from affected&#xD;
      skin, improve symptoms of AD, and improve AD-related quality of life. This Phase 2 study is&#xD;
      designed to compare the efficacy of treatment with benralizumab versus placebo and compare&#xD;
      benralizumab maintenance dosing regimens in the extension period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">March 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 11, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with an IGA 0/1 and a decrease in IGA of ≥ 2 points at Week 16 relative to baseline</measure>
    <time_frame>Week 16 for all patients</time_frame>
    <description>Scale Title: Investigator Global Assessment Score (IGA) Minimum Value: 0 - Clear Maximum Value: 4 - Severe High score means a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with skin clearance (EASI-75)</measure>
    <time_frame>Week 16 for all patients</time_frame>
    <description>Scale Title: Eczema Area and Severity Index (EASI)&#xD;
Area Score:&#xD;
Minimum Value: 0 - No active eczema in this region Maximum Value: 6 - The entire region is affected by eczema&#xD;
Severity Score:&#xD;
Minimum Value: 0 - None Maximum Value: 3 - Severe High score means a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum benralizumab concentration and anti-drug antibodies (ADA)</measure>
    <time_frame>Week 16 for all patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with skin clearance (EASI-90)</measure>
    <time_frame>Week 16 for all patients</time_frame>
    <description>Scale Title: Eczema Area and Severity Index (EASI)&#xD;
Area Score:&#xD;
Minimum Value: 0 - No active eczema in this region Maximum Value: 6 - The entire region is affected by eczema&#xD;
Severity Score:&#xD;
Minimum Value: 0 - None Maximum Value: 3 - Severe High score means a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with an improvement of ≥ 4 or more points in peak pruritus weekly score</measure>
    <time_frame>Week 16 for all patients</time_frame>
    <description>Scale Title: Peak Pruritus Rating Scale Minimum Value: 0 - No itch Maximum Value: 10 - Worst itch imaginable High score means a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in DLQI and CDLQI</measure>
    <time_frame>Week 16 for all patients</time_frame>
    <description>Scale Title: Dermatology Life Quality Index Minimum Value - Not at all/Not relevant Maximum Value - Very much&#xD;
Scale Title: Children's Dermatology Life Quality Index Minimum Value - Not at all Maximum Value - Very much High score means a worse outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Benralizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo / Benralizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Benralizumab</intervention_name>
    <description>Benralizumab by subcutaneous injection until Week 16, and then benralizumab by subcutaneous injection during the extension period.</description>
    <arm_group_label>Benralizumab</arm_group_label>
    <other_name>Benralizumab, Benra, Fasenra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo / Benralizumab</intervention_name>
    <description>Placebo by subcutaneous injection until Week 16, then benralizumab by subcutaneous injection until Week 52.</description>
    <arm_group_label>Placebo / Benralizumab</arm_group_label>
    <other_name>Benralizumab, Benra, Fasenra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Physician-confirmed diagnosis of AD (according to American Academy of Dermatology&#xD;
             Consensus Criteria) that is not adequately controlled with topical medications.&#xD;
&#xD;
          2. EASI score of ≥ 12 at screening and ≥ 16 at randomization.&#xD;
&#xD;
          3. IGA score of ≥ 3 (on a scale of 0 to 4, in which 3 is moderate and 4 is severe) at&#xD;
             screening and at randomization.&#xD;
&#xD;
          4. Atopic dermatitis involvement of ≥ 8% body- surface area at screening and ≥ 10%&#xD;
             body-surface area at randomization.&#xD;
&#xD;
          5. A pruritus numerical rating scale average score for maximum itch intensity of ≥ 4,&#xD;
             based on the average of daily pruritus numerical rating scale scores for maximum itch&#xD;
             intensity reported during the 7 days prior to randomization.&#xD;
&#xD;
          6. Documented recent history (within 6 months prior to screening) of inadequate response&#xD;
             to treatment with topical medications, or patients for whom topical treatments are&#xD;
             otherwise medically inadvisable (eg, because of important side effects or safety&#xD;
             risks).&#xD;
&#xD;
          7. Participants that have applied a stable dose of topical emollient (moisturizer) twice&#xD;
             daily for ≥ 7 consecutive days immediately before the randomization visit. (NOTE: See&#xD;
             exclusion criterion 11 for limitations regarding emollients)&#xD;
&#xD;
          8. Participants must be willing and able to complete daily PRO assessments:&#xD;
&#xD;
               -  Complete at least 70% of daily PRO assessments between Visit 1 and Visit 2 and&#xD;
&#xD;
               -  Complete at least 5 of 7 daily PRO assessments in the 7 days prior to Visit 2.&#xD;
&#xD;
          9. Females of childbearing potential (FOCBP) must agree to use a highly effective method&#xD;
             of birth control (confirmed by the Investigator) from randomization, throughout the&#xD;
             study duration, and within 16 weeks after last dose of IP and have a negative serum&#xD;
             pregnancy test result on Visit 1.&#xD;
&#xD;
         10. Females not of childbearing potential are defined as females who are either&#xD;
             permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral&#xD;
             salpingectomy) or who are postmenopausal. Females will be considered postmenopausal if&#xD;
             they have been amenorrheic for ≥ 12 months prior to the planned date of randomization&#xD;
             without an alternative medical cause. The following age-specific requirements apply:&#xD;
&#xD;
               1. Females &lt; 50 years old will be considered postmenopausal if they have been&#xD;
                  amenorrheic for 12 months or more following cessation of exogenous hormonal&#xD;
                  treatment and with follicle-stimulating hormone (FSH) levels in the&#xD;
                  postmenopausal range. Until FSH is documented to be within menopausal range, the&#xD;
                  participant should be treated as a FOCBP.&#xD;
&#xD;
               2. Females ≥ 50 years old will be considered postmenopausal if they have been&#xD;
                  amenorrheic for 12 months or more following cessation of all exogenous hormonal&#xD;
                  treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants with active dermatological conditions (eg, psoriasis, seborrheic&#xD;
             dermatitis, cutaneous lymphoma) other than atopic dermatitis that, in the&#xD;
             investigator's opinion, may interfere with the study assessments&#xD;
&#xD;
          2. Known active allergic or irritant contact dermatitis that, in the investigator's&#xD;
             opinion, may interfere with the study assessments&#xD;
&#xD;
          3. Current malignancy, or history of malignancy, with the exception of:&#xD;
&#xD;
               1. Participants who have had basal cell carcinoma, localized squamous cell carcinoma&#xD;
                  of the skin, or in situ carcinoma of the cervix are eligible provided that the&#xD;
                  participant is in remission and curative therapy was completed at least 12 months&#xD;
                  prior to the date informed consent, was obtained.&#xD;
&#xD;
               2. Participants who have had other malignancies are eligible provided that the&#xD;
                  participant is in remission and curative therapy was completed at least 5 years&#xD;
                  prior to the date informed consent, was obtained.&#xD;
&#xD;
          4. Any disorder, including, but not limited to, cardiovascular, gastrointestinal,&#xD;
             hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic,&#xD;
             hematological, psychiatric, or major physical impairment that is not stable in the&#xD;
             opinion of the Investigator and could:&#xD;
&#xD;
               1. Affect the safety of the participant throughout the study&#xD;
&#xD;
               2. Influence the findings of the studies or their interpretations&#xD;
&#xD;
               3. Impede the participant's ability to complete the entire duration of study.&#xD;
&#xD;
          5. History of anaphylaxis to any biologic therapy or vaccine&#xD;
&#xD;
          6. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed&#xD;
             consent is obtained that has not been treated with, or has failed to respond to&#xD;
             standard of care therapy&#xD;
&#xD;
          7. Any clinically significant abnormal findings in physical examination, vital signs,&#xD;
             hematology, clinical chemistry, or urinalysis during screening/run-in period which, in&#xD;
             the opinion of the Investigator, may put the participant at risk because of his/her&#xD;
             participation in the study, or may influence the results of the study, or the&#xD;
             participant's ability to complete entire duration of the study&#xD;
&#xD;
          8. Current active liver disease:&#xD;
&#xD;
               1. Chronic stable hepatitis B and C (including positive testing for hepatitis B&#xD;
                  surface antigen [HBsAg] or hepatitis C antibody), or other stable chronic liver&#xD;
                  disease are acceptable if participant otherwise meets eligibility criteria.&#xD;
                  Stable chronic liver disease should generally be defined by the absence of&#xD;
                  ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric&#xD;
                  varices, or persistent jaundice, or cirrhosis.&#xD;
&#xD;
               2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥ 3&#xD;
                  times the upper limit of normal (ULN), confirmed by repeated testing during the&#xD;
                  run-in period. Transient increase of AST/ALT level that resolves by the time of&#xD;
                  randomization is acceptable if in the Investigator's opinion the participant does&#xD;
                  not have an active liver disease and meets other eligibility criteria.&#xD;
&#xD;
          9. A history of known immunodeficiency disorder including a positive human&#xD;
             immunodeficiency virus (HIV) test Prior/concomitant Therapy&#xD;
&#xD;
         10. Participants who have received treatment for AD with TCS, topical calcineurin&#xD;
             inhibitors (TCI), or topical phosphodiesterase-4 (PDE4) inhibitors within the 7 days&#xD;
             prior to the randomization visit&#xD;
&#xD;
         11. Initiation of treatment of AD with prescription moisturizers or moisturizers&#xD;
             containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation&#xD;
             products during the screening period (patients may continue using stable doses of such&#xD;
             moisturizers if initiated before the screening visit)&#xD;
&#xD;
         12. Regular use (2 visits per week) of a tanning booth/parlor or phototherapy for AD&#xD;
             within 4 weeks prior to the randomization visit&#xD;
&#xD;
         13. Use of immunosuppressive medication including, but not limited to: methotrexate,&#xD;
             cyclosporine, azathioprine, systemic corticosteroids within 4 weeks or 5 half-lives&#xD;
             prior to the date informed consent is obtained, whichever is longer.&#xD;
&#xD;
             Other&#xD;
&#xD;
         14. Receipt of immunoglobulin or blood products within 30 days prior to the date informed&#xD;
             consent is obtained&#xD;
&#xD;
         15. Receipt of any marketed or investigational biologic within 4 months or 5 half-lives&#xD;
             prior to the date informed consent is obtained, whichever is longer&#xD;
&#xD;
         16. Receipt of live attenuated vaccines 30 days prior to first dose of IP&#xD;
&#xD;
         17. Receipt of any investigational nonbiologic within 30 days or 5 half-lives prior to the&#xD;
             date informed consent is obtained, whichever is longer&#xD;
&#xD;
         18. Previously received benralizumab (MEDI-563, FASENRA)&#xD;
&#xD;
         19. Change to allergen immunotherapy or new allergen immunotherapy within 30 days prior to&#xD;
             the date of informed consent and anticipated changes in immunotherapy throughout the&#xD;
             study&#xD;
&#xD;
         20. Planned elective major surgical procedures during the conduct of the study&#xD;
&#xD;
         21. Previous randomization in the present study&#xD;
&#xD;
         22. Concurrent enrollment in another clinical trial&#xD;
&#xD;
         23. AstraZeneca staff involved in the planning and/or conduct of the study&#xD;
&#xD;
         24. For females only: Currently pregnant, breastfeeding, or lactating females A serum&#xD;
             pregnancy test will be done for FOCBP at Visit 1 and a urine pregnancy test must be&#xD;
             performed for FOCBP at each subsequent treatment visit prior to IP administration. A&#xD;
             positive urine test result must be confirmed with a serum pregnancy test. If serum&#xD;
             test is positive, the participant should be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emma Guttman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MOUNT SINAI HOSPITAL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westminster</city>
        <state>California</state>
        <zip>92683</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sugarloaf</city>
        <state>Pennsylvania</state>
        <zip>18249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fremantle</city>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kotara</city>
        <zip>2289</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phillip</city>
        <zip>02606</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sippy Downs</city>
        <zip>4556</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodville South</city>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woolloongabba</city>
        <zip>04102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haskovo</city>
        <zip>6300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruse</city>
        <zip>7013</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1463</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1680</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 10</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 10</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <zip>110 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest Cedex 2</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille CEDEX 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille Cedex 8</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nice cedex 3</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Mande</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ansan-si</city>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gwangju</city>
        <zip>61453</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyeongsangnam-do</city>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <zip>21431</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>5030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-033</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osielsko</city>
        <zip>86031</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <zip>60-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-262</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manises</city>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D3256C00001&amp;amp;attachmentIdentifier=220141e8-ba2f-4aea-a044-80a5876025af&amp;amp;fileName=HILLIER_Brochure_V01_USA.pdf&amp;amp;versionIdentifier=</url>
    <description>HILLIER Brochure</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D3256C00001&amp;amp;attachmentIdentifier=b97b714c-8163-4691-b923-9d3cff3c16c6&amp;amp;fileName=HILLIER_Flyer_V01_USA.pdf&amp;amp;versionIdentifier=</url>
    <description>HILLIER Flyer</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D3256C00001&amp;amp;attachmentIdentifier=5d60250f-ea3e-458b-8532-570d4c4a89c1&amp;amp;fileName=HILLIER_Patient_Brochure_V02_AUS(en)02.pdf&amp;amp;versionIdentifier=</url>
    <description>HILLIER Patient Brochure</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D3256C00001&amp;amp;attachmentIdentifier=8b961fc2-8fec-4c92-a573-9ea37c22a9cf&amp;amp;fileName=HILLIER_Patient_Flyer_V01_AUS(en).pdf&amp;amp;versionIdentifier=</url>
    <description>HILLIER Patient Flyer</description>
  </link>
  <link>
    <url>https://www.benradermtrials.com/</url>
    <description>A website on the HILLIER study</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate to severe atopic dermatitis</keyword>
  <keyword>pruritus</keyword>
  <keyword>skin lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benralizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.&#xD;
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

